
Molecules p. 5898 - 5912 (2014)
Update date:2022-08-02
Topics:
Oliveira, Claudio B. S.
Meurer, Ywlliane S. R.
Oliveira, Marianne G.
Medeiros, Wendy M. T. Q.
Silva, Francisco O. N.
Brito, Ana C. F.
De Pontes, Daniel L.
Andrade-Neto, Valter F.
A resorcinarene derivative of vanillin, resvan, was synthesized and characterized by spectroscopic techniques. We measured the cytotoxicity (in vivo and in vitro), antioxidant and anti-Toxoplasma activities of vanillin and the resorcinarene compound. Here we show that vanillin has a dose-dependent behavior with IC50 of 645 μg/mL through an in vitro cytotoxicity assay. However, we could not observe any cytotoxic response at higher concentrations of resvan (IC50 > 2,000 μg/mL). The in vivo acute toxicity assays of vanillin and resvan exhibited a significant safety margin indicated by a lack of systemic and behavioral toxicity up to 300 mg/kg during the first 30 min, 24 h or 14 days after administration. The obtained derivative showed greater antioxidative activity (84.9%) when comparing to vanillin (19.4%) at 1,000 μg/mL. In addition, vanillin presents anti-Toxoplasma activity, while resvan does not show that feature. Our findings suggest that this particular derivative has an efficient antioxidant activity and a negligible cytotoxic effect, making it a potential target for further biological investigations.
Nanjing Habo Medical Technology Co., Ltd.
Contact:025-85769882
Address:No.108. Ganjiabian east. Qixia District .Nanjing
Hangzhou jls Flame Retardants Chemical Co.,Ltd
Contact:+86-571-87250387/87250386
Address:MOGANSHAN RODA 1418# SHANGCHENG INDUSTRIAL PARK
Yangzhou Siyu Chemical Co.,Ltd.
Contact:+86-514-87325867 13358126196
Address:Room 620 Exposition Pavilion,No. 98 Huaihai Road,Guangling District,Yangzhou City, Jiangsu Province
Contact:86-371-63655023
Address:No.85,jinshui road,zhengzhou,China
Shanghai Coupling Pharmaceutical R&D Co., Ltd.(expird)
Contact:+86 021 50106671
Address:403 Room No.4 Buiding, No. 526 Ruiqing Road, Shanghai Zhangjiang Hi-Tech Park
Doi:10.1055/s-0030-1259545
(2011)Doi:10.1007/s00044-015-1474-x
(2016)Doi:10.1021/jo5005394
(2014)Doi:10.1246/cl.2012.420
(2012)Doi:10.1021/ol2012204
(2011)Doi:10.1016/j.bmcl.2010.11.103
(2011)